

Cancer Treatment Protocol Compliance

Clinical Rationale

Medicare Advantage plans are required to provide coverage for cancer drugs and biologics listed in the National Comprehensive Cancer Network (NCCN) compendia for evidence levels 2A and above.¹ For many cancers, the NCCN provides multiple options with evidence levels 2A and above. Humana and its vendors promote the use of the most-effective, least-toxic and least-costly alternatives when there are multiple options for cancer treatment via the Oncology Quality Management program.²

Medical oncologists are measured on their adherence rates to the highest quality, least toxic and least costly alternative regimens.

Measure At A Glance



Applicable Specialties
Oncology



Measure Steward
Humana proprietary*



Measure Description
Patients with cancer for whom the physician's chemotherapy treatment protocol demonstrates compliance with national, local and other recognized compendia and published standards of care; and represents the most-effective and least-toxic choice.

References

*Humana proprietary measure. Humana propriety measures are grounded on evidence-based medicine, are supported by credible organizations and aid in improved health outcomes.

1. National Comprehensive Cancer Network. NCCN categories of evidence and consensus.
<https://www.nccn.org/guidelines/guidelines-process/development-and-update-of-guidelines>.
2. National Comprehensive Cancer Network (NCCN). Library of NCCN compendia.
<https://www.nccn.org/professionals/compendia.aspx>.